Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Sonia Dolinger runs a meal delivery business and fundraises for cancer research. She has chronic lymphocytic leukemia.
The monoclonal antibody reduces the risk of disease progression or death by 45%.
More than 70% of people treated with Abecma, a customized immunotherapy, experienced complete or partial remission.
Natural immunity and vaccine responses may be weaker in people with immune suppression, so they should get their second dose promptly.
Researchers have identified another molecule that may lead to the development of more effective targeted medications.
Heidi Yates, who has chronic lymphocytic leukemia, has the grit it takes to fight for a good life with chronic blood cancer.
The reluctance comes despite serious risk of COVID-19 complications for people with blood cancers such as leukemia and lymphoma.
Nearly a quarter of patients treated with the peptide-drug conjugate experienced partial remission.
After approval of the latest cellular therapy for non-Hodgkin lymphoma, the big challenge is how to extend it to common solid tumors.
Umbralisib led to remission in 49% of patients with marginal zone lymphoma and 43% of those with follicular lymphoma.
The coronavirus vaccines are safe and should be effective even for people with advanced cancer.
Damon Runyon Cancer Research Foundation shares some exciting discoveries made by Damon Runyon researchers in 2020.
Xpovio (selinexor) was approved for adults with multiple myeloma who have received at least one prior therapy.
Studies ask whether cancer treatment, such as chemotherapy and immunotherapy, can lead to more severe COVID-19.
Poorer outcomes for Black and Hispanic patients significantly depend on where they live.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.